CN Patent

CN106692150B — 尼达尼布在制备预防和治疗肝纤维化与肝硬化的药物中的用途

Assigned to 302th Hospital of PLA · Expires 2019-08-20 · 7y expired

What this patent protects

本发明涉及尼达尼布在制备预防和治疗肝纤维化与肝硬化的药物中的用途。本发明证明了尼达尼布可以明显改善肝纤维化或肝硬化的程度，减轻肝损伤，并且无明显的肝细胞毒性，具备良好的应用前景。

USPTO Abstract

本发明涉及尼达尼布在制备预防和治疗肝纤维化与肝硬化的药物中的用途。本发明证明了尼达尼布可以明显改善肝纤维化或肝硬化的程度，减轻肝损伤，并且无明显的肝细胞毒性，具备良好的应用前景。

Drugs covered by this patent

Patent Metadata

Patent number
CN106692150B
Jurisdiction
CN
Classification
—
Expires
2019-08-20
Drug substance claim
No
Drug product claim
No
Assignee
302th Hospital of PLA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.